Fc- and CDR-modified humanised monoclonal antibody against C5

( DrugBank: - / KEGG DRUG: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
11	Myasthenia gravis	8
62	Paroxysmal nocturnal hemoglobinuria	26

ID	Disease name (Link within this page)	Number of trials
109	Atypical hemolytic uremic syndrome	13

11. Myasthenia gravis

Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

trials per page:

Showing 1 to 8 of 8 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-003243-39-PT (EUCTR)	15/06/2020	06/02/2020	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR ...	Alexion Pharmaceuticals Incorporated	NULL	Not Recruiting	Female: yes Male: yes	160	Phase 3	United States;Portugal;Spain;Austria;Russian Federation;Israel;United Kingdom;Switzerland;Italy;Fran ...
2	EUCTR2018-003243-39-GB (EUCTR)	11/02/2020	08/10/2019	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 3	Portugal;United States;Spain;Turkey;Austria;Russian Federation;Israel;Italy;United Kingdom;Switzerla ...
3	EUCTR2018-003243-39-CZ (EUCTR)	02/01/2020	13/09/2019	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 3	Portugal;United States;Spain;Turkey;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingd ...
4	EUCTR2018-003243-39-AT (EUCTR)	09/10/2019	26/04/2019	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Ravulizumab Other descriptive nam ...	Alexion Pharmaceuticals Incorporated	NULL	Not Recruiting	Female: yes Male: yes	160	Phase 3	United States;Portugal;Spain;Austria;Russian Federation;Israel;United Kingdom;Switzerland;Italy;Fran ...
5	EUCTR2018-003243-39-DK (EUCTR)	20/09/2019	22/05/2019	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 3	Portugal;United States;Czechia;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Czech Re ...
6	EUCTR2018-003243-39-DE (EUCTR)	30/07/2019	25/03/2019	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 3	United States;Czechia;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Czech Republic;Ca ...
7	EUCTR2018-003243-39-NL (EUCTR)	22/07/2019	01/05/2019	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 3	United States;Portugal;Czechia;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Czech Re ...
8	EUCTR2018-003243-39-ES (EUCTR)	21/05/2019	27/05/2019	Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthen ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety an ...	Generalized Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Mya ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	160	Phase 3	United States;Canada;Spain;Denmark;Austria;Israel;Netherlands;Germany;Japan;Italy;Switzerland;Korea, ...

First Previous1Next Last

62. Paroxysmal nocturnal hemoglobinuria

Clinical trials : 292 / Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108

trials per page:

Showing 1 to 10 of 26 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-002370-39-DE (EUCTR)	02/07/2019	15/11/2018	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label,Pharmacokinetic, Noninferiority Study ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Not Recruiting	Female: yes Male: yes	105	Phase 3	Russian Federation;United States;United Kingdom;Spain;Canada;Austria;Czech Republic;Netherlands;Swed ...
2	EUCTR2017-002370-39-NL (EUCTR)	01/07/2019	27/11/2018	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label,Pharmacokinetic, Noninferiority Study ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	105	Phase 3	United States;Czechia;Finland;Spain;Turkey;Austria;Russian Federation;United Kingdom;Italy;France;Cz ...
3	EUCTR2017-002370-39-CZ (EUCTR)	09/04/2019	02/01/2019	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label,Pharmacokinetic, Noninferiority Study ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 20.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Not Recruiting	Female: yes Male: yes	105	Phase 3	Russian Federation;United States;United Kingdom;Spain;Canada;Czech Republic;Austria;Netherlands;Swed ...
4	EUCTR2017-002370-39-AT (EUCTR)	01/04/2019	24/01/2019	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label,Pharmacokinetic, Noninferiority Study ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Not Recruiting	Female: yes Male: yes	105	Phase 3	United States;Finland;Spain;Turkey;Austria;Russian Federation;United Kingdom;Italy;France;Czech Repu ...
5	EUCTR2017-002370-39-SE (EUCTR)	27/03/2019	30/11/2018	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label,Pharmacokinetic, Noninferiority Study ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	105	Phase 3	United States;Czechia;Finland;Spain;Turkey;Austria;Russian Federation;United Kingdom;Italy;France;Cz ...
6	EUCTR2017-002370-39-BE (EUCTR)	13/03/2019	23/11/2018	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label,Pharmacokinetic, Noninferiority Study ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	105	Phase 3	United States;Czechia;Finland;Spain;Turkey;Austria;Russian Federation;United Kingdom;Italy;France;Cz ...
7	EUCTR2017-002370-39-GB (EUCTR)	19/02/2019	26/11/2018	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Stud ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	105	Phase 3	United States;Finland;Spain;Turkey;Austria;Russian Federation;Italy;United Kingdom;France;Czech Repu ...
8	EUCTR2017-002370-39-ES (EUCTR)	08/02/2019	18/01/2019	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Stud ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 20.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	105	Phase 3	United States;Finland;Spain;Turkey;Austria;Russian Federation;Italy;United Kingdom;France;Czech Repu ...
9	EUCTR2017-002370-39-FI (EUCTR)	29/01/2019	21/12/2018	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label,Pharmacokinetic, Noninferiority Study ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	105	Phase 3	United States;Czechia;Finland;Spain;Turkey;Austria;Russian Federation;United Kingdom;Italy;France;Cz ...
10	EUCTR2017-002370-39-FR (EUCTR)	28/12/2018	20/11/2018	This study compares the pharmacokinetics (PK) of ravulizumab subcutaneous (SC) administered via an o ...	A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Stud ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 20.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised m ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	105	Phase 3	United States;Finland;Spain;Turkey;Austria;Russian Federation;Italy;United Kingdom;France;Czech Repu ...

First Previous1 2 3Next Last

109. Atypical hemolytic uremic syndrome

Clinical trials : 114 / Drugs : 36 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 11

trials per page:

Showing 1 to 10 of 13 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-002499-29-FR (EUCTR)	07/06/2019	15/03/2018	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised monoclonal antibody agains ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	16	Phase 3	United States;France;Belgium;Spain;Austria;Germany;Italy;United Kingdom;Sweden
2	EUCTR2016-002499-29-BE (EUCTR)	18/08/2017	11/05/2017	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Ravulizumab Other descriptive nam ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	23	Phase 3	United States;Taiwan;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Belgium;Aus ...
3	EUCTR2016-002499-29-IT (EUCTR)	16/08/2017	30/01/2018	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised monoclonal antibody agains ...	Alexion Pharmaceuticals Incorporated	NULL	Not Recruiting	Female: yes Male: yes	16	Phase 3	France;United States;Belgium;Spain;Austria;Germany;United Kingdom;Italy;Sweden
4	EUCTR2016-002027-29-BE (EUCTR)	22/06/2017	28/02/2017	Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients w ...	Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients w ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised monoclonal antibody agains ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	55	Phase 3	United States;Spain;Austria;United Kingdom;Italy;France;Czech Republic;Belgium;Australia;Germany;Jap ...
5	EUCTR2016-002499-29-SE (EUCTR)	21/06/2017	21/03/2017	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Ravulizumab Other descriptive nam ...	Alexion Pharmaceuticals Incorporated	NULL	Not Recruiting	Female: yes Male: yes	23	Phase 3	United States;Taiwan;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Belgium;Aus ...
6	EUCTR2016-002499-29-ES (EUCTR)	31/05/2017	31/03/2017	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 19.1;Level: LLT;Classification code 100195 ...	Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised monoclonal antibody agains ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	16	Phase 3	United States;Spain
7	EUCTR2016-002499-29-DE (EUCTR)	24/05/2017	15/02/2017	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Ravulizumab Other descriptive nam ...	Alexion Pharmaceuticals Inc.	NULL	Not Recruiting	Female: yes Male: yes	23	Phase 3	United States;Taiwan;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Belgium;Aus ...
8	EUCTR2016-002499-29-GB (EUCTR)	18/05/2017	09/02/2017	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised monoclonal antibody agains ...	Alexion Pharmaceuticals Incorporated	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	23	Phase 3	United States;Taiwan;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Belgium;Aus ...
9	EUCTR2016-002499-29-AT (EUCTR)	28/04/2017	08/03/2017	Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)	A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemol ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: Ravulizumab Other descriptive nam ...	Alexion Pharmaceuticals Incorporated	NULL	Not Recruiting	Female: yes Male: yes	23	Phase 3	United States;Taiwan;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Belgium;Aus ...
10	EUCTR2016-002027-29-SE (EUCTR)	19/04/2017	16/02/2017	Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients w ...	Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients w ...	Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.0;Level: LLT;Classification code 100195 ...	Product Code: ALXN1210 INN or Proposed INN: Fc- and CDR-modified humanised monoclonal antibody agains ...	Alexion Pharmaceuticals Incorporated	NULL	Not Recruiting	Female: yes Male: yes	55	Phase 3	United States;France;Czech Republic;Belgium;Spain;Austria;Australia;Germany;United Kingdom;Japan;Kor ...

First Previous1 2Next Last